Search results
Showing 76 to 83 of 83 results for atezolizumab
In development [GID-TA11165] Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 739.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.